{
    "text_blocks": {
        "data": {
            "block_count": 16,
            "table_index": 1
        },
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "votes": {
                    "0": "1",
                    "1": "1",
                    "2": "1"
                },
                "decision": "1"
            },
            "gpt-4o-2024-08-06": {
                "votes": null,
                "decision": null
            }
        },
        "timestamp": "2025-01-21_09-38-03"
    },
    "table_comments": {
        "data": "Consolidated Balance Sheets\tDecember 31,\t(in millions, except per share amounts)\t2020\t2019\t",
        "timestamp": "2025-03-11_12-29-35"
    },
    "units": {
        "data": {
            "sum_units": 1000000,
            "sum_divider": 1.0
        },
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "votes": {
                    "0": "1000000",
                    "1": "1000000"
                },
                "decision": "1000000"
            },
            "gpt-4o-2024-08-06": {
                "votes": null,
                "decision": null
            }
        },
        "timestamp": "2025-03-11_12-29-38"
    },
    "post_table_text": {
        "data": "\tSee accompanying notes.\t55\tGILEAD SCIENCES, INC.\tConsolidated Statements of Income\tY",
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "trials": {
                    "0": "'\tSee accompanying notes.\t55\tGILEAD SCIENCES, INC.\tConsolidated Statements of Income\tY'"
                },
                "decision": "'\tSee accompanying notes.\t55\tGILEAD SCIENCES, INC.\tConsolidated Statements of Income\tY'"
            },
            "gpt-4o-2024-08-06": {
                "trials": {},
                "decision": null
            }
        },
        "timestamp": "2025-03-11_12-29-41"
    },
    "table_body": {
        "data": "Assets\tCurrent assets:\tCash and cash equivalents\t$\t5,997\t$\t11,631\tShort-term marketable securities\t1,411\t12,721\tAccounts receivable, net\t4,892\t3,582\tInventories\t1,683\t922\tPrepaid and other current assets\t2,013\t1,440\tTotal current assets\t15,996\t30,296\tProperty, plant and equipment, net\t4,967\t4,502\tLong-term marketable securities\t502\t1,488\tIntangible assets, net\t33,126\t13,786\tGoodwill\t8,108\t4,117\tOther long-term assets\t5,708\t7,438\tTotal assets\t$\t68,407\t$\t61,627\tLiabilities and Stockholders  Equity\tCurrent liabilities:\tAccounts payable\t$\t844\t$\t713\tAccrued government and other rebates\t3,460\t3,473\tOther accrued liabilities\t4,336\t3,074\tCurrent portion of long-term debt and other obligations, net\t2,757\t2,499\tTotal current liabilities\t11,397\t9,759\tLong-term debt, net\t28,645\t22,094\tLong-term income taxes payable\t5,016\t6,115\tOther long-term obligations\t5,128\t1,009\tCommitments and contingencies (Note 14)\tStockholders  equity:\tPreferred stock, par value $\t0.001\tper share;\t5\tshares authorized;\tno\tne outstanding\t \t \tCommon stock, par value $\t0.001\tper share;\t5,600\tauthorized;\t1,254\tand\t1,266\tshares issued and outstanding, respectively\t1\t1\tAdditional paid-in capital\t3,880\t3,051\tAccumulated other comprehensive income\t(\t60\t)\t85\tRetained earnings\t14,381\t19,388\tTotal Gilead stockholders  equity\t18,202\t22,525\tNoncontrolling interest\t19\t125\tTotal stockholders  equity\t18,221\t22,650\tTotal liabilities and stockholders  equity\t$\t68,407\t$\t61,627",
        "timestamp": "2025-03-11_12-29-41"
    },
    "table_json_created": {
        "data": true,
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "trials": {
                    "0": "{\"Assets\": {\"Current assets\": {\"Cash and cash equivalents\": [5997, 11631], \"Short-term marketable securities\": [1411, 12721], \"Accounts receivable, net\": [4892, 3582], \"Inventories\": [1683, 922], \"Prepaid and other current assets\": [2013, 1440], \"Total current assets\": [15996, 30296]}, \"Property, plant and equipment, net\": [4967, 4502], \"Long-term marketable securities\": [502, 1488], \"Intangible assets, net\": [33126, 13786], \"Goodwill\": [8108, 4117], \"Other long-term assets\": [5708, 7438], \"Total assets\": [68407, 61627]}, \"Liabilities and Stockholders Equity\": {\"Current liabilities\": {\"Accounts payable\": [844, 713], \"Accrued government and other rebates\": [3460, 3473], \"Other accrued liabilities\": [4336, 3074], \"Current portion of long-term debt and other obligations, net\": [2757, 2499], \"Total current liabilities\": [11397, 9759]}, \"Long-term debt, net\": [28645, 22094], \"Long-term income taxes payable\": [5016, 6115], \"Other long-term obligations\": [5128, 1009], \"Commitments and contingencies\": null, \"Stockholders equity\": {\"Preferred stock, par value $ 0.001 per share; 5 shares authorized; no one outstanding\": [0, 0], \"Common stock, par value $ 0.001 per share; 5,600 authorized; 1,254 and 1,266 shares issued and outstanding, respectively\": [1, 1], \"Additional paid-in capital\": [3880, 3051], \"Accumulated other comprehensive income\": [-60, 85], \"Retained earnings\": [14381, 19388], \"Total Gilead stockholders equity\": [18202, 22525], \"Noncontrolling interest\": [19, 125], \"Total stockholders equity\": [18221, 22650]}, \"Total liabilities and stockholders equity\": [68407, 61627]}}"
                },
                "decision": "{\"Assets\": {\"Current assets\": {\"Cash and cash equivalents\": [5997, 11631], \"Short-term marketable securities\": [1411, 12721], \"Accounts receivable, net\": [4892, 3582], \"Inventories\": [1683, 922], \"Prepaid and other current assets\": [2013, 1440], \"Total current assets\": [15996, 30296]}, \"Property, plant and equipment, net\": [4967, 4502], \"Long-term marketable securities\": [502, 1488], \"Intangible assets, net\": [33126, 13786], \"Goodwill\": [8108, 4117], \"Other long-term assets\": [5708, 7438], \"Total assets\": [68407, 61627]}, \"Liabilities and Stockholders Equity\": {\"Current liabilities\": {\"Accounts payable\": [844, 713], \"Accrued government and other rebates\": [3460, 3473], \"Other accrued liabilities\": [4336, 3074], \"Current portion of long-term debt and other obligations, net\": [2757, 2499], \"Total current liabilities\": [11397, 9759]}, \"Long-term debt, net\": [28645, 22094], \"Long-term income taxes payable\": [5016, 6115], \"Other long-term obligations\": [5128, 1009], \"Commitments and contingencies\": null, \"Stockholders equity\": {\"Preferred stock, par value $ 0.001 per share; 5 shares authorized; no one outstanding\": [0, 0], \"Common stock, par value $ 0.001 per share; 5,600 authorized; 1,254 and 1,266 shares issued and outstanding, respectively\": [1, 1], \"Additional paid-in capital\": [3880, 3051], \"Accumulated other comprehensive income\": [-60, 85], \"Retained earnings\": [14381, 19388], \"Total Gilead stockholders equity\": [18202, 22525], \"Noncontrolling interest\": [19, 125], \"Total stockholders equity\": [18221, 22650]}, \"Total liabilities and stockholders equity\": [68407, 61627]}}"
            },
            "gpt-4o-2024-08-06": {
                "trials": {},
                "decision": null
            }
        },
        "timestamp": "2025-03-12_11-31-12"
    },
    "problems": {
        "data": [],
        "timestamp": "2025-03-12_11-31-12"
    }
}